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Introduction: Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast
and gastric cancers. However, patients may develop resistance through downstream signaling via the
phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to determine the safety and
tolerability of the investigational AKT inhibitor MK-2206, to prepare for future studies to determine whether the
combination with trastuzumab could inhibit compensatory signaling.
Methods: Patients with HER2+ treatment-refractory breast and gastroesophageal cancer were enrolled. Treatment
consisted of standard doses of intravenous trastuzumab and escalating dose levels of oral MK-2206 using either an
every-other-day (45 mg and 60 mg QOD) or once-weekly (135 mg and 200 mg QW) schedule.
Results: A total of 34 patients with HER2+ disease were enrolled; 31 received study-drug. The maximum tolerated
dose (MTD) for MK-2206 in combination with trastuzumab was 60 mg for the QOD schedule and 135 mg for the
QW schedule, although a true MTD was not established due to early termination of the trial. The most common
treatment-emergent toxicities included fatigue, hyperglycemia, and dermatologic rash, consistent with prior
experience; one death unrelated to treatment was reported. There was one complete response in a patient with
metastatic breast cancer, one patient achieved a partial response, and 5 patients had stable disease for at least 4
months, despite progression on multiple prior trastuzumab- and lapatinib-based therapies. Results also indicate
that trastuzumab does not affect the pharmacokinetics of MK-2206.
Conclusions: Results suggest the AKT inhibitor MK-2206 can be safely combined with trastuzumab, and is asso-
ciated with clinical activity, supporting further investigation.
Trial registration: ClinicalTrials.gov; identifier: NCT00963547.Introduction
Approximately 20 to 25% of breast cancers [1,2] and
30% of gastric cancers [3] have overexpression and/or
gene amplification of human epidermal growth factor
receptor 2 (HER2), which serves as both a poor prognos-
tic marker and a therapeutic target. HER2 amplification,
detected by fluorescence in situ hybridization, or overex-
pression, determined by immunohistochemistry staining,* Correspondence: hudisc@mskcc.org
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reproduction in any medium, provided the orpredicts responsiveness to HER2-targeted agents, such
as trastuzumab, lapatinib, and other newer agents. How-
ever, patients with metastatic HER2+ breast cancer or
gastric cancer may have intrinsic resistance or develop
partial or complete clinical resistance to HER2-targeted
therapy during the course of treatment [4-6]. Under-
standing mechanisms of resistance could lead to the
development of new strategies to overcome resistance in
these patients. One mechanism of resistance to trastuzu-
mab is mediated through activation of downstream
signaling via the phosphatidylinositol-3 kinase (PI3K)/
AKT pathway, which has been identified as a majortd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7,8]. Several groups have shown that HER2+ breast
cancer models that have been selected for trastuzumab
resistance can be effectively targeted with PI3K or AKT
inhibitors [9,10]. The potential to increase antitumor
activity by blocking both AKT signaling and HER2
kinase has been further suggested by a study showing
that combined inhibition of AKT and HER2 kinase activ-
ity is more effective than either one alone in HER2+
models [11].
MK-2206 is an investigational allosteric inhibitor of
AKT that requires the PH domain of AKT for activity,
but does not interact with the ATP binding pocket. As a
result, MK-2206 is highly selective for AKT inhibition,
has higher potency against recombinant human AKT1
and AKT2 isoforms than AKT3, has little off-target kin-
ase activities, and is less vulnerable to feedback activa-
tion of AKT compared with ATP-competitive inhibitors
[12]. In prior phase 1 studies, MK-2206 was tested in
over 100 patients with solid tumors using an every other
day (QOD) or once weekly (QW) dosing schedule [13].
Overall, MK-2206 was well tolerated at biologically ac-
tive doses, with the maximum tolerable dose (MTD)
established at 60 mg QOD; the MTD for the QW dosing
schedule (expected to be less than 250 mg) was not
established due to early discontinuation of the trial. The
most significant dose-limiting toxicity (DLT) was rash,
which was maculopapular in nature with a truncal
distribution, and was distinct from the acneiform rash
seen with epidermal growth factor receptor inhibitors.
Pharmacokinetic testing revealed that MK-2206 has a
long half-life (60 to 90 hours) and no substantial depart-
ure from dose proportionality, and preliminary evidence
of clinical activity was seen in various tumors. Based on
the preclinical rationale for the combination of MK-
2206 and trastuzumab, as well as promising preclinical
results, we conducted a phase 1 trial to evaluate the
QOD and QW dosing schedules from earlier trials and
to determine the MTD and recommended phase 2 dose
for MK-2206, administered in combination with stand-
ard doses of trastuzumab. We also assessed early clinical
evidence of antitumor activity of this combination in
patients with HER2+ solid tumors.
Methods
Study design and treatment plan
This phase 1, multicenter, open-label, nonrandomized,
dose-defining study was conducted in accordance with the
Declaration of Helsinki and the International Conference
on Harmonisation Good Clinical Practice Guidelines, and
was approved by relevant regulatory and independent
ethics committees including Memorial Sloan-Kettering
Cancer Center’s Institutional Review Board, Mofftt Cancer
Center’s Quorum Review Institutional Review Board, andThe National Research Ethics Service, The Royal Marsden
Research Ethics Committee. Patients provided written con-
sent prior to enrolling in the trial. The primary objective of
the study was to determine the safety and tolerability, de-
fine the DLTs and MTD, and determine the recommended
phase 2 dose of MK-2206 in combination with trastuzu-
mab. Dose finding was based on toxicity probability inter-
vals [14]. In brief, three patients were first dosed at each
level and advanced according to the toxicity probability
interval; up to another 10 patients (total of 13 patients at a
dose level) could be assigned to one dose, in which case up
to four DLT events in the dose level of 13 patients would
be considered tolerable. Secondary objectives of the trial
were to explore the antitumor activity and pharmacokinet-
ics of MK-2206 in combination with trastuzumab in pa-
tients with advanced HER2+ solid tumors. Correlation of
antitumor activity with PI3K pathway activation events
(that is, circulating tumor DNA and mutations) was an
exploratory objective of this trial.
Trastuzumab 8 mg/kg was administered as a standard
intravenous infusion (loading dose) on day 1 followed by
6 mg/kg every 3 weeks. Oral MK-2206 was given either
as a 45 mg or 60 mg dose QOD in two cohorts, or as a
135 mg and 200 mg dose QW in two cohorts; patients
were enrolled in parallel in the two MK-2206 dosing
schedules. Treatment continued until disease progres-
sion, development of unacceptable toxicity, or patient
withdrawal of consent. Dose modification of oral MK-
2206 was permitted for patients who experienced grade
2 or higher drug-related toxicities (that were not clinic-
ally manageable) after the first cycle of treatment. No
dose modifications were planned for trastuzumab during
the course of the study, unless a patient experienced a
toxicity not specified in the protocol. Patients were
evaluated every 3 months by computed tomography or
magnetic resonance imaging scans. Overall tumor re-
sponse and progression were evaluated according to the
Response Evaluation Criteria in Solid Tumors guidelines
(RECIST v1.0).
Patient eligibility
Patients 18 years of age or older with Eastern Coopera-
tive Oncology Group performance status 0 to 1 and ad-
equate hematologic, kidney, and liver function, and with
histologically or cytologically confirmed locally advanced
or metastatic HER2+ solid tumors, were eligible for the
trial. Patients with significant cardiac disease or known
active central nervous system metastases and/or carcin-
omatous meningitis were not eligible – unless they had
completed radiation or were clinically stable for 1 month
prior to entry without evidence of new or enlarging
central nervous system metastasis, and were no longer
taking steroids for brain edema. Patients who were re-
ceiving trastuzumab and/or lapatinib prior to screening
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if trastuzumab was administered at 2 mg/kg per week,
or for 3 weeks if trastuzumab was administered at 6 mg/
kg per week; other chemotherapeutic or experimental
agents were not allowed within 30 days of entering the
trial. Since MK-2206 is metabolized by cytochrome
p450 3A4, patients using potent cytochrome p450 3A4
inhibitors or inducers had to be off the medication for at
least 14 days before the first dose of the study medica-
tions. Pregnant or lactating women were not eligible for
enrollment.
Safety, tolerability, and toxicity assessment
Patients were evaluated at baseline and throughout the
course of the study using physical examinations, vital
signs, ophthalmologic examinations, 12-lead electrocar-
diogram cardiac monitoring, laboratory tests, and Eastern
Cooperative Oncology Group performance status. Patients
were also monitored carefully for the development of ad-
verse events (AEs) during treatment with MK-2206 in
combination with trastuzumab; AEs were graded according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0. Hematological and
nonhematological DLTs occurring within the first 21 days
of cycle 1 were used to determine the MTD of MK-2206 in
combination with trastuzumab. Hematological DLTs were
defined as grade 4 neutropenia lasting 5 days or more,
grade 3 or 4 neutropenia with fever >38.5°C and/or infec-
tion requiring antibiotic or antifungal treatment, and grade
4 thrombocytopenia (≤25.0 × 109/l). Nonhematological
DLTs included any grade 3 or higher toxicity, with the
specific exception of grade 3 nausea, vomiting, diarrhea, or
dehydration with inadequate treatment lasting <48 hours;
asthenia; inadequately treated hypersensitivity reactions;
grade 3 elevated transaminases lasting <1 week; and
isolated nonfasting grade 3 glucose without adequate
supportive care measures. Additional DLTs included any
drug-related AE, regardless of National Cancer Institute
Common Terminology Criteria for Adverse Events grade,
leading to a dose modification of MK-2206 in the first cycle;
unresolved grade 2 or higher drug-related AEs requiring
drug interruption for 8 days or more in the first cycle; and
unresolved drug-related AEs requiring drug interruption
for a total of 15 days or more in the first cycle.
Pharmacokinetic and nucleic acid analysis
Sampling for pharmacokinetic determinations was con-
ducted in all patients from each dose level during the
first and second cycles of therapy. Plasma samples were
collected to determine concentrations of MK-2206 on
day 1 predose and at 2, 4, 6, 10, 24 (predose day 2), and
48 hours (predose day 3) after the first dose of study
medication for cycle 1 and cycle 2. On days 7 and 15 of
cycle 1, samples were collected immediately prior to theadministration of MK-2206. Plasma concentration of MK-
2206 was used to determine pharmacokinetic parameters,
including the peak plasma concentration (Cmax), time to
maximum concentration, minimum plasma concentration,
and area under the concentration–time curve (AUC), as
described previously by Yap and colleagues [13].
We requested that all patients enrolled in this study
submit formalin-fixed, paraffin-embedded tumor tissue
for analysis of loss of PTEN and mutations in PIK3CA
and related genes. A separate fresh whole blood sample
was collected at baseline to isolate circulating tumor nu-
cleic acids in order to detect mutations in PIK3CA, spe-
cifically codons encoding amino acids E542, E545, and
H1047.
Statistical analyses
Since the primary objective of the trial was to determine
the safety and tolerability of MK-2206 in combination
with trastuzumab, the trial sample size depended pri-
marily on clinical rather than statistical considerations.
Specifically, the final number of subjects enrolled in the
study was dependent on empirical safety (DLT) observa-
tions. All patients who received at least one dose of
study treatment were assessed for safety data, and de-
scriptive tables summarizing the number and percentage
of patients who experienced AEs were generated. No ef-
ficacy target was predefined since antitumor activity was
a secondary objective of the trial. The response rate and
95% confidence intervals were determined for response
to treatment data, and summary statistics were gener-
ated for pharmacokinetic data.
Results
Patient characteristics
From September 2009 to February 2011, 44 patients
were screened at three participating sites; 34 were en-
rolled in the trial and 31 patients received study medica-
tions. Three patients (one patient allocated to the QOD
cohort and two patients allocated to the QW cohort)
withdrew consent prior to receiving the first dose of
treatment. Among the 31 patients treated, three patients
were in the 45 mg QOD cohort, 11 patients were in the
60 mg QOD cohort, 11 patients were in the 135 mg
QW cohort, and six patients were in the 200 mg QW
cohort (Figure 1). There were 27 patients with breast
cancer and four patients with gastric cancers, and the
majority of patients (93.5%) had received at least three
prior lines of therapy. Table 1 summarizes the demo-
graphics and baseline characteristics of the 31 patients
who were enrolled in the trial and received treatment.
Treatment tolerability
The combination of trastuzumab and MK-2206 was gen-







































Figure 1 Patient flowchart. DLT, dose-limiting toxicity; QOD, every other day; QW, every week.
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two cohorts of 45 mg and 60 mg QOD, and the QW co-
horts were tested at 135 mg and 200 mg. There were no
DLTs in the 45 mg QOD cohort, but among the 11 pa-
tients treated with 60 mg QOD one patient developed a
DLT (grade 2 skin rash requiring dose modification).
Among the 11 patients in the 135 mg QW cohort, one
patient experienced two DLTs of grade 1 and grade 2
skin rash requiring dose modification. Among the six
patients in the 200 mg QW cohort, two patients were
not evaluable due to rapid progression and were taken
off the study before the end of first cycle; two of the four
evaluable patients developed DLTs (one with grade 2
maculopapular skin rash, and one with grade 3 skin rash
and grade 3 hypersensitivity). The 200 mg QW cohort
was therefore judged not to be tolerable in this popula-
tion of heavily pretreated breast and gastroesophageal
cancer patients. Due to the early termination of the trial
when the sponsor withdrew support, we were not able
to determine a true MTD for MK-2206. However, the 60
mg QOD and 135 mg QW doses may represent the
MTD in combination with the standard dose of trastu-
zumab administered (although the true MTD may be
higher).
Among the patients treated, the most common
treatment-emergent AEs occurring in at least 40% of pa-
tients in any treatment group included fatigue, hypergly-
cemia, rash, nausea, increase in liver enzymes, and
decreased appetite (Table 2). There was one reporteddeath during the course of the trial (malignant neo-
plasm), which was considered unrelated to treatment
with MK-2206 in combination with trastuzumab. No
clear patterns or apparent differences in adverse experi-
ences were observed between the 60 mg QOD and 135
mg QW cohorts.
Clinical response
Among the evaluable patients who were treated with
study medications for at least one cycle, one patient
achieved complete response (CR), one patient had partial
response (PR), and five patients had stable disease (SD)
for 4 months or longer (one SD patient treated for over
5 months had unconfirmed PR by the investigators).
Based on data collected by the time of discontinuation
of the study (database lock), the clinical benefit response
rate (CR, PR, and SD ≥4 months) was determined to be
24%, and the median time to progression was 72 days
(range 13 to 173 days). One patient, who continued
treatment after database lock, received 18 cycles of ther-
apy (for a total of 388 days) before discontinuing due to
skin rash. Details of patients who responded to treat-
ment are presented in Table 3; all patients who achieved
CR and PR had breast cancer, and a single male patient
with gastric cancer achieved SD as a best response. The
patient with gastric cancer had not received trastuzumab
in the past, while all the other patients with breast can-
cer had progressed on trastuzumab with an interval
from the last dose of trastuzumab of 0 to 68 days. The




45 mg QOD 60 mg QOD 135 mg QW 200 mg QW All cohorts
(n = 3) (n = 11) (n = 11) (n = 6) (N = 31)
Gender, n (%)
Male 0 (0.0) 1 (9.1) 0 (0.0) 2 (33.3) 3 (9.7)
Female 3 (100.0) 10 (90.9) 11 (100.0) 4 (66.7) 28 (90.3)
Age (years)
Median 44 55.5 49 48.5 51.5
Range 36 to 52 44 to 67 37 to 61 38 to 59 36 to 67
Cancer type, n (%)
Breast 3 (100.0) 10 (90.9) 11 (84.6) 3 (50.0) 27 (87.1)
Gastric 0 (0.0) 1 (9.1) 0 (0.0) 3 (50.0) 4 (12.9)
Cancer stage, n (%)
Intravenous 3 (100.0) 11 (100.0) 11 (100.0) 6 (100.0) 31 (100.0)
ECOG status, n (%)
0 3 (75.0) 7 (63.6) 10 (91.0) 4 (66.7) 24 (77.4)
1 0 (0.0) 4 (36.4) 1 (9.0) 2 (33.3) 7 (22.6)
Number of prior therapies, n (%)
1 or 2 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 2 (6.5)
≥3 3 (100.0) 11 (100.0) 11 (100.0) 4 (66.7) 29 (93.5)
ECOG, Eastern Cooperative Oncology Group; QOD, every other day; QW, every week.
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progressive chest wall lesions while on trastuzumab; dur-
ing the course of our study, the metastatic skin lesions
completely resolved after two cycles of treatment. Unfor-
tunately, this patient elected to stop receiving treatmentTable 2 Treatment-emergent adverse events occurring
in ≥30% of patients treated with MK-2206 plus
trastuzumab (n = 31)






Fatigue 71.0 0 0
Hyperglycemia 51.8 6.5 0
Rash 58.1 16.7 0
Nausea 48.4 0 0




Decreased appetite 41.9 0 0




Decreased hemoglobin 32.3 3.2 0
Dyspepsia 32.3 0 0
Hypoalbuminenia 32.3 0 0
Vomiting 32.3 0 0due to a flare-up of ulcerative colitis (possibly related to
treatment) during cycle 6 of treatment. The time to pro-
gression for all enrolled patients and the best target
lesion response are depicted in Figure 2.
Pharmacokinetics
Mean plasma concentrations of MK-2206 administered
as 45 mg or 60 mg QOD doses and as 135 mg or 200
mg QW doses with a standard dose regimen of trastuzu-
mab are shown in Figure 3. MK-2206 was absorbed, with
median time to maximum concentration ranging from 4
to 6 hours after co-administration of 45 mg or 60 mg
QOD doses of MK-2206 with trastuzumab, and 4 to 8
hours after 135 mg and 200 mg QW doses of MK-2206
with trastuzumab. Interindividual variability of plasma
concentrations were moderate to high; a small number
of patients received a 45 mg MK-2206 QOD dose
(n = 3); only two patients completed dosing of 200 mg
MK-2206 QW and pharmacokinetic sampling in cycle 1
as scheduled. The mean accumulation ratio of Cmax and
AUC0 to 48 hours after multiple doses over 21 to 24 days,
expressed as the geometric mean ratio last dose/first
dose, ranged from 2.34 to 2.76 for the 45 mg and 60 mg
QOD doses. The effective half-life determined from
Cmax and AUC accumulations ratio ranged from 60 to
96 hours, consistent with the mean terminal half-life of
63 to 89 hours for MK-2206 alone, and suggests
that elimination of MK-2206 was not altered after co-























5 41 Progressive disease 167 SD
(unconfirmed
PR)




4 21 Progressive disease 164 SD




2 0 Trastuzumab not given 171 SD




8 48 Unknown 219 SD




5 68 Completed therapy 105 SD




3 0 Progressive disease 388 (withdraw)a PR




5 28 Progressive disease 106 (withdraw) CR
CR, complete response; HER2, human epidermal growth factor receptor 2; PR, partial response; QOD, every other day; QW, every week; SD, stable disease. aPatient
was on trial for 173 days and then continued receiving treatment after database lock for a total of 388 days before withdrawing due to skin rash.
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ratios of Cmax after multiple dosing for 21 to 22 days
(last dose/first dose) for patients on the 135 mg and 200
mg MK-2206 QW dosing schedule were 1.26 and 1.30,
respectively. The effective half-life based on accumula-
tion ratio of Cmax and AUC was 74 to 79 hours. Similar
geometric mean ratios were obtained for AUC0 to 48 hours
after QW dosing with trastuzumab. The pharmacoki-
netic results were consistent with data from a prior
monotherapy study of MK-2206, suggesting that trastu-
zumab did not appreciably alter the pharmacokinetics of
MK-2206. In addition, the trough levels of all patients
(11/11) receiving 45 mg or 60 mg QOD doses of
MK-2206 with trastuzumab was at or above the clinical
monotherapy efficacy trough target of 56.8 nM. Similarly,
10 out of 11 (~92%) patients receiving 135 mg or 200 mg
QW doses of MK-2206 also achieved the 48-hour target of
at least 56.8 nM.
Circulating nucleic acid
All patients enrolled in the study had a baseline blood
sample collection for analysis of circulating nucleic acid
for mutations in PIK3CA. Only three of the 37 patients
enrolled were found to have PIK3CA gene mutations:
two patients with breast cancer who went on to receive
treatment had an H1047L mutation in exon 9 and an
E545K mutation, and the third patient had a less
predominant M1043I mutation but withdrew prior to
documentation of progression of disease.
Discussion
Trastuzumab is effective therapy for HER2+ breast can-
cers and gastric cancers. However, relative resistance totrastuzumab is common via multiple mechanisms [5-8].
Through unbiased RNA interference screening analyses,
activation of the PI3K pathway has been implicated as a
major mediator of trastuzumab resistance [7]. Based on
these data and preclinical findings that HER2 signaling
is highly dependent on PI3K/AKT signaling [10], we hy-
pothesized that tumors could have compensatory activa-
tion of this pathway, thereby avoiding the impact of
HER2 inhibitors. To begin clinical exploration of com-
bined HER2 and AKT signaling blockade, we evaluated
treatment with trastuzumab and the allosteric AKT in-
hibitor MK-2206 in this phase 1 study. Previously,
monotherapy with MK-2206 given either QOD or QW
was tolerable, leading us to examine both dosing sched-
ules combined with trastuzumab [13,15]. The majority
of patients enrolled in the study had exposure to trastu-
zumab and had progressed on treatment. Our study
demonstrated that the combination of trastuzumab and
MK-2206 was as tolerable as the same dosing schedule
using MK-2206 monotherapy, with no evidence of en-
hanced toxicities with combined therapy. A true MTD
for MK-2206 in combination with trastuzumab was not
established, but the 60 mg QOD and 135 mg QW doses
are reasonable doses for future evaluation in phase 2 tri-
als. The pharmacokinetic profile of MK-2206 in this
study was similar to that observed when MK-2206 was
administered as monotherapy. In addition, the DLT of
the combination therapy was skin rash, which was the
same as the DLT of MK-2206 given as monotherapy.
Other observed AEs were also consistent with those of
MK-2206 single-agent therapy.
The combination of MK-2206 and trastuzumab also
demonstrated preliminary evidence of therapeutic efficacy
CA
B
200 mg QW + trastuzumab
135 mg QW + trastuzumab
60 mg QOD + trastuzumab
45 mg QOD + trastuzumab
Figure 2 Activity of MK-2206 following treatment with the combination of MK-2206 and trastuzumab in patients with human epidermal
growth factor receptor 2-positive breast cancer or gastric cancer. (A) Time to progression for all patients enrolled who progressed during the trial
and (B) best change in the size of target lesions from baseline, following treatment with the combination of MK-2206 and trastuzumab in patients with
human epidermal growth factor receptor 2-positive breast cancer or gastric cancer. One patient achieved complete response and one patient had partial
response; both patients withdrew from the study due to adverse events and are not included in (A). In (B), Patient 01719 had a 41% decrease in tumor size
while on trial and achieved an overall 68% decrease in the size of target lesions while continuing to receive treatment after discontinuation of the
study. (C) One patient with breast cancer who achieved complete response had an area of erythematous skin lesion on the operative site at baseline
(left panel) that completely resolved after receiving two cycles of treatment at the 60 mg every other day (QOD) MK-2206 dose level (right panel). QW,
every week.
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cancer, with a clinical benefit response rate of approxi-
mately 24% and a median time to progression of 72 days.
One patient with metastatic breast cancer, whose disease
progressed on the right chest wall around the previousmastectomy scar while on maintenance therapy with tras-
tuzumab, achieved CR following combination therapy with
MK-2206. Her erythematous chest wall skin lesion showed
a dramatic improvement after receiving two cycles of study
treatment and by 6 months the skin lesion had completely
Figure 3 Mean MK-2206 plasma concentration profiles following administration of MK-2206 in combination with trastuzumab. Linear
scale of plasma concentration following administration of MK-2206, in every other day (QOD) and every week (QW) schedules, in combination
with trastuzumab.
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cer treated for over a year experiencing a total reduction in
tumor size of 68% who was confirmed as having PR. Five
more patients had SD for more than 4 months. These
preliminary efficacy results suggest that the combination of
MK-2206 with trastuzumab may offer patients an effective
salvage regimen following progression on trastuzumab, or
may prevent or delay clinical resistance if used earlier in the
disease.
The efficacy observed in this phase 1 study supports
the hypothesis that a mechanism of resistance to trastu-
zumab may be mediated by activation of the PI3K/AKT
pathway in vivo. The mechanisms through which the
PI3K/AKT pathway may be activated in trastuzumab-
refractory HER2+ tumors is currently unknown. Leading
candidates include activating mutations of the PIK3CA
gene or deletion or mutations in PTEN, an inhibitor of
the PI3K/AKT pathway. We collected circulating nucleic
acid to explore this possibility, based on reports that cor-
related findings in circulating nucleic acid with DNA
from tumor specimens [16]. Only three patients were
found to have mutations in the PIK3CA gene in circulat-
ing DNA and none had notably long SD or response to
treatment. No PIK3CA mutation was detected in the
circulating nucleic acid samples from patients who
responded to treatment. Studies have estimated that
between 13 and 31% of HER2+ breast cancers harbor
mutations in PIK3CA [17]. Results of PIK3CA mutation
status from circulating DNA in this study (two of 27
HER2+ breast cancer patients who received treatment)are at the lower limit of these estimations. One of the
limitations of this analysis is that our PIK3CA mutation
assessment was restricted to circulating DNA analysis.
Tumor biopsies for biomarker analysis prior to treat-
ment were not mandated and intratumor heterogeneity
in PIK3CA mutation status or limitations of detection
inherent to circulating DNA mutational analysis may be
responsible for the lower than expected PIK3CA muta-
tional frequency observed. The possibility therefore re-
mains that tumor samples at primary or metastatic sites
might demonstrate mutations that do not appear in
circulating nucleic acid.
Despite these caveats, our analysis of the circulating
DNA PIK3CA somatic mutation status does not support
the hypothesis that tumors with PIK3CA mutations
have improved responsiveness to MK-2206. Conceivably,
other molecular aberrations such as p95HER2, PTEN
loss of function events or alternative signaling cascades
mediated by HER3, and insulin growth factor-1 recep-
tors or epidermal growth factor receptors that were not
assessed in our study, may also be predicted to render
tumors resistant to trastuzumab but sensitive to com-
bined AKT inhibition. Therefore, in an attempt to pre-
dict preferential benefit from combined AKT inhibitor/
trastuzumab therapy, exploratory biomarker analyses
may need to consider the polygenic nature of trastuzu-
mab resistance and assess multiple aberrations in the
HER2 signaling pathway in each tumor. This finding is
consistent with the recent report of the combination of
trastuzumab and everolimus, a mammalian target of
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strating loss of PTEN were associated with poorer
overall survival, although loss of PTEN and/or PI3KCA
mutations did not seem to affect progression-free sur-
vival, compared with those without genetic alterations.
Additional studies are needed to generate more data to
fully determine the potential role of circulating DNA
mutations as predictors of drug sensitivity in this
population.
Numerous agents specifically targeting dysregulated
molecular pathways, believed to be key tumorigenic
drivers, have recently been approved or are being evalu-
ated as potential treatment options in patients with
breast cancer or other tumor types [19]. Combined anti-
body therapy, using both trastuzumab and chemother-
apy with or without pertuzumab, was recently shown to
be effective [20]. However, nonchemotherapeutic ap-
proaches are attractive because they promise reduced
toxicity. For example, a phase 3 trial evaluated the com-
bination of trastuzumab and the small molecule, revers-
ible inhibitor of epidermal growth factor receptor and
HER2, lapatinib, in HER2+ metastatic breast cancer pa-
tients refractory to trastuzumab administered in the ab-
sence of chemotherapy [21]. Results from this trial,
which enrolled 296 patients, demonstrated improve-
ments in overall survival, progression-free survival and
clinical benefit response in the combination arm com-
pared with treatment with lapatinib alone. However, the
difference in median progression-free survival – specific-
ally between the two treatment arms – was only 4 weeks
(12.0 weeks in the combination group vs. 8.1 weeks in
the lapatinib monotherapy group), and the majority of
patients did not achieve a dramatic improvement in
tumor response rate or survival, suggesting that the
combined blockade of HER2 signaling is active even
without chemotherapy, but may not be sufficient to
overcome downstream PI3K/AKT pathways responsible
for resistance to trastuzumab.
Based on results from our phase 1 study, we believe
that additional translational studies of MK-2206 with
trastuzumab and possibly other agents including pan-
HER kinase inhibitors (for example, lapatinib or nerati-
nib) or broad cytotoxic agents (for example, paclitaxel)
are warranted. Treatment with MK-2206 has been
shown to upregulate HER3 via feedback mechanisms
limiting antitumor effects, which could be rescued by
the addition of lapatinib [11]. Early phase clinical trials
are already underway investigating the combination of
MK-2206 and lapatinib in patients with advanced or
metastatic solid tumors or breast cancer.
Conclusions
Our results show evidence of antitumor activity in pa-
tients with HER2+ breast cancer and gastroesophagealcancer following treatment with standard doses of tras-
tuzumab and MK-2206, and the combination was gen-
erally well tolerated. Trastuzumab did not affect the
pharmacokinetic profile of MK-2206, suggesting that
this AKT inhibitor can be safely combined with trastu-
zumab. Our results support further investigations with
MK-2206 in combination with HER2 inhibitors or
cytotoxic agents for patients with treatment-refractory
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